Taysha Gene Therapies recently received FDA Breakthrough Therapy Designation for its Rett syndrome gene therapy TSHA-102, following encouraging REVEAL trial results and protocol alignment to enable a ...
MALVERN, Pa., Dec. 21, 2023 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a biotechnology company focused on discovering, developing, and commercializing novel gene and cell ...
Taysha Gene Therapies, Inc. (NASDAQ:TSHA) stock is trading lower on Friday, with a session volume of 4.695 million, as per data from Benzinga Pro. On Thursday, during after-hours trading, the company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback